AGPU Axe Compute Inc.
Axe Compute Inc. provides access to graphics processing unit and digital asset treasury strategy. The company operates through two segments: Compute Services and Treasury Management; and Drug Discovery Services. The Comp…
Industry Peers
Software - Infrastructure| Headline | Source | Time |
|---|---|---|
Older | ||
 Axe Compute Just Sold Its Cancer Business to Become an AI Stock Axe Compute stock has rallied over 650% in the past six months as investors increasingly value it as an AI infrastructure stock. The challenge is now delivering on that promise. | ||
 Why DataMEDS’ Acquisition Does Not Seem to Be Very Bullish for MEDS Stock at This Point The low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI. | ||
 DataMEDS AI Completes $1.5 Million Helomics Acquisition, Expanding into Cancer Diagnostics The transaction adds a certified oncology laboratory, contract research services and $1. 5 million in cash to DataMEDS, while Axe Compute exits its remaining cancer testing business. | ||
 One stock quietly did 590% in 2026 after a decisive AI rebranding The company now rents out AI computing power as Axe Compute. | ||
Exclusive: Axe Compute CEO says prepayments cover about a third of $3bn build cost Investing.com -- The $317 million in customer prepayments Axe Compute has received represents roughly 30% to 35% of the total cost of building out its $3 billion contract book, chief executive Christopher Miglino told Investing.com. | ||
 Duos Technologies’ AI Transformation Has Wall Street’s Attention. Here’s How Big This $300 Million Market Cap Company Could Get. Duos' latest quarter offers the clearest evidence yet that its transformation into an AI data-center company is starting to pay off. | ||
Axe Compute Inc (AGPU) (Q2 2026) Earnings Call Highlights: $3 Billion in New Contracts and ... Company reports record contract signings, first customer prepayment, and outlines path to over $696 million annualized revenue as deployment scales. | ||
 DUOT Stock Eyes Best Single-Day Gains In 20 Months — Cantor Says $500M Data Center Lease Should Drive A 'Sharp' Revenue Inflection By Q1 Next Year Analysts at Cantor Fitzgerald raised their price target on Duos to $27 from $26 while maintaining an ‘Overweight’ rating, implying an upside potential of about 118% from current levels. | ||
 Duos Technologies Group, Inc. Q2 2026 Earnings Call Summary Moby summary of Duos Technologies Group, Inc.'s Q2 2026 earnings call | ||
Duos Technologies Group Inc (DUOT) (Q2 2026) Earnings Call Highlights: Pure-Play AI ... Duos Technologies Group Inc (DUOT) transforms into an AI infrastructure leader with a 65-megawatt contracted capacity and a robust 2027 revenue framework of at least $160 million. | ||
 Duos Technologies Group Q2 Earnings Call Highlights Duos Technologies Group (NASDAQ:DUOT) said its second-quarter results reflected the completion of its shift from rail technology toward edge data centers, AI infrastructure and technology solutions, supported by divestitures, new customer agreements and a substantially larger cash balance. Chief Ex | ||
DUOT Stock Soars On Five-Year Hosting Agreements Worth Over 18X Its 2025 Revenue — What Investors Need To Know Duos Technologies said that the agreements cover an aggregate 55 MW of AI facility capacity across multiple U.S. data center sites | ||
 A $1.5 Billion Reason to Buy Axe Compute Stock Axe Compute's expanding pipeline of Nvidia Blackwell AI projects has fueled optimism, but weak financial results and execution risks remain key concerns. | ||
 This Week In Cloud AI - Axe Compute Secures Major $1.5 Billion AI Infrastructure Deal Axe Compute Inc. has announced a significant five-year customer agreement valued at over $1.5 billion, marking a notable development in the Cloud AI space. This contract involves the deployment of a dedicated AI infrastructure cluster based on NVIDIA Blackwell GPUs, intended for high-demand AI workloads in the United States. The agreement, secured through Axe Compute's Build program, is part of a larger effort, bringing the company's total signed contract value for 2026 to over $3 billion... | ||
Top Midday Decliners China Pharma (CPHI) priced its registered direct offering of 2.5 million common shares at $2 each, t | ||